Ketamine in Chronic Kid's (KiCK) Pain

• Status: Terminated
• Trial end date: 2015-05-01
• Target enrollment: 0
• Participant gender: All

Summary

This study is designed to select the most tolerable dose of oral ketamine for children with chronic pain. Children will be given either placebo or one of three dosages of oral ketamine for 2 weeks. The dosage that is most tolerable will be selected for further study.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Medical University of South Carolina
• Treatments: Ketamine

Criteria

Inclusion Criteria:

• Subject, parent, or guardian willing and able to give informed consent

• NRS for pain over the past 24 hours >4 at baseline

• Chronic pain, which has been present for >3 months, or persisting longer than is normal for the underlying diagnosis

• Chronic pain related to physiologic diagnoses including but not limited to: cancer, rheumatologic disease, sickle cell anemia, cystic fibrosis, pancreatitis, and neuromuscular disease (e.g. Duchenne muscular dystrophy)

• Able to tolerate and cooperate with neurocognitive assessment

• Age 8-20 years old

Exclusion Criteria:

• If they are known or suspected to have drug addiction

• Uncontrolled psychiatric disorder such as depression, schizophrenia, or bipolar disorder

• Uncontrolled hypertension

• Known liver disease or elevation of AST or ALT greater than 3 times the upper limit of normal.

• Previous intolerance or allergic reaction to ketamine

• Pregnancy

• Use of CYP3A4 inhibitors or inducers within the 2-week period prior the study drug administration or within 5 half-lives of the respective medication, whichever is longer, until study conclusion.

• Consumption of grapefruit or grapefruit products from at least 2 weeks prior to study drug administration until study conclusion.